이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Genscript Biotech 관리

관리 기준 확인 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Weihui Shao

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	3yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	3.6yrs
이사회 평균 재임 기간	5.3yrs

최근 관리 업데이트

Recent updates

CEO

Weihui Shao (44 yo)

3yrs

테뉴어

Ms. Weihui Shao is Chief Operating Officer of Genscript Biotech Corporation from July 08, 2021 and serves as its Rotating Chief Executive Officer since January 01, 2023. She joined the Genscript Biotech Co...

리더십 팀

이름	위치	테뉴어	보상	소유권
Jiange Meng	Executive Chairman	8.9yrs	US$1.07m	0.013% $ 2.4m
Weihui Shao	CEO & COO	3yrs	데이터 없음	0.021% $ 3.9m
Ye Wang	Co-Founder	22.5yrs	US$615.00k	0.037% $ 6.7m
Shiniu Wei	Chief Financial Officer	3.6yrs	데이터 없음	데이터 없음
Fangliang Zhang	co-founder & Executive Director	1.6yrs	US$271.00k	데이터 없음
Li Zhu	Chief Strategy Officer & Executive Director	3.7yrs	US$529.00k	0.058% $ 10.6m
Wai Ling Wong	Company Secretary	8.9yrs	데이터 없음	데이터 없음

3.6yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 1548 의 관리팀은 경험 ( 3.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jiange Meng	Executive Chairman	8.9yrs	US$1.07m	0.013% $ 2.4m
Ye Wang	Co-Founder	9.2yrs	US$615.00k	0.037% $ 6.7m
Fangliang Zhang	co-founder & Executive Director	2.2yrs	US$271.00k	데이터 없음
Li Zhu	Chief Strategy Officer & Executive Director	3.7yrs	US$529.00k	0.058% $ 10.6m
Carl June	Member of Advisory Board	less than a year	데이터 없음	데이터 없음
George Church	Member of Advisory Board	4.8yrs	데이터 없음	데이터 없음
David Liu	Member of Scientific Advisory Board	less than a year	데이터 없음	데이터 없음
Zumian Dai	Independent Non-Executive Director	8.9yrs	US$105.00k	0.00021% $ 38.5k
Xuehai Wang	Independent Non-Executive Director	3.7yrs	US$120.00k	데이터 없음
Luquan Wang	Non-Executive Director	9.2yrs	데이터 없음	0.030% $ 5.5m
Jiuan Pan	Independent Non-Executive Director	5.7yrs	US$124.00k	0.00021% $ 38.5k
Jiafen Wang	Non-Executive Director	5.7yrs	US$51.00k	0.00019% $ 34.9k

5.3yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 1548 의 이사회는 경험(평균 재직 기간 7.2 년)으로 간주됩니다.

Genscript Biotech 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Recent updates

Genscript Biotech Corporation Announces Board Resignations and Changes in Composition of Board Committees

GenScript Biotech Corporation Launches FLASH Gene Service: The Most Affordable Gene Synthesis Solution on the Market

Now 22% undervalued after recent price drop

GenScript Biotech Corporation Announces Self-Amplifying RNA Synthesis Service for Advanced Therapeutic Applications

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Now 25% undervalued after recent price drop

Insider recently sold HK$1.0m worth of stock

Genscript Biotech Corporation Announces Directorate Appointments and Change in Composition of Board Committee

Board Member recently sold HK$455k worth of stock

Genscript Biotech Corporation, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: US$0.045 loss per share (vs US$0.11 loss in FY 2022)

Genscript Announces Appointment of Dr. David R. Liu to the Scientific Advisory Board

Genscript Biotech Corporation to Report Fiscal Year 2023 Final Results on Mar 09, 2024

New minor risk - Profitability

Executive Chairman recently sold HK$610k worth of stock

GenScript Biotech Corporation Expands its IVT mRNA Synthesis Portfolio with Addition of Customized Circular RNA and Lipid Nanoparticles Formulation Services

First half 2023 earnings released: US$0.044 loss per share (vs US$0.063 loss in 1H 2022)

Genscript Biotech Corporation to Report First Half, 2023 Results on Aug 19, 2023

Insider recently sold HK$1.4m worth of stock

Full year 2022 earnings released: US$0.11 loss per share (vs US$0.17 loss in FY 2021)

Now 24% undervalued

Now 20% undervalued

Genscript Biotech Corporation Announces Chief Executive Officer Changes

Genscript Biotech Corporation Announces Redesignation of Dr. Zhang Fangliang from A Non-Executive Director to an Executive Director with Effect from December 17, 2022

Less than half of directors are independent

First half 2022 earnings released: US$0.063 loss per share (vs US$0.046 loss in 1H 2021)

Genscript Biotech Corporation to Report First Half, 2022 Results on Aug 31, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Six Months Ended June 30, 2022

Genscript Biotech Corporation Announces Board Changes

Genscript Biotech Corporation Announces Board Changes

Full year 2021 earnings released: US$0.17 loss per share (vs US$0.11 loss in FY 2020)

Less than half of directors are independent

Genscript Biotech Corporation, Annual General Meeting, May 27, 2022

Genscript Biotech Corporation Provides Earnings Guidance for the Year Ended 31 December 2021

Board Member recently sold HK$2.1m worth of stock

First half 2021 earnings released: US$0.046 loss per share (vs US$0.06 loss in 1H 2020)

Key Executive recently sold HK$9.1m worth of stock

Duke-NUS Medical School and GenScript Biotech Corporation Announce Notice of Allowance for U.S. Patent Application for SARS-CoV-2 Surrogate Virus Neutralization Test

Hillhouse Capital Management, Ltd. completed the acquisition of 2.99% stake in Genscript Biotech Corporation (SEHK:1548) from GenScript Corporation.

Full year 2020 earnings released: US$0.11 loss per share (vs US$0.052 loss in FY 2019)

Full year 2020 earnings released

Genscript Biotech Corporation to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: HK$14.66

Genscript Probio and Neoletix Announce Successful Completion of 200-Liter Gmp Production Runs of Recombinant Coagulation Fviii Based on A Novel Production Technology

New 90-day low: HK$10.18

New 90-day low: HK$10.36

Genscript Biotech Corporation Announces Board and Director Changes

New 90-day low: HK$11.38

Co-Founder recently bought HK$3.7m worth of stock

First half earnings released

New 90-day low: HK$11.48

First half earnings released

New 90-day low - HK$14.96

Genscript Biotech Corporation to Report Q2, 2020 Results on Aug 29, 2020

Genscript Biotech Corporation Announces Management Changes Effective 2 August 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령